Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel and bevacizumab has on sarcoma.
Sarcoma|Leiomyosarcoma|Malignant Fibrous|Histiocytoma|Angiosarcoma
DRUG: gemcitabine|DRUG: docetaxel|DRUG: bevacizumab
Overall Objective Response, Overall Objective Response will be evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1), 6 months
The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel and bevacizumab has on sarcoma.